- Home
- KOPN vs TVRD Comparison
KOPN vs TVRD Comparison
Compare KOPN & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOPN
- TVRD
- Stock Information
- Founded
- KOPN 1984
- TVRD 2017
- Country
- KOPN United States
- TVRD United States
- Employees
- KOPN N/A
- TVRD N/A
- Industry
- KOPN Semiconductors
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- KOPN Technology
- TVRD Health Care
- Exchange
- KOPN Nasdaq
- TVRD Nasdaq
- Market Cap
- KOPN 255.1M
- TVRD 246.5M
- IPO Year
- KOPN 1992
- TVRD N/A
- Fundamental
- Price
- KOPN $1.89
- TVRD $28.05
- Analyst Decision
- KOPN Strong Buy
- TVRD Strong Buy
- Analyst Count
- KOPN 2
- TVRD 5
- Target Price
- KOPN $2.63
- TVRD $59.20
- AVG Volume (30 Days)
- KOPN 2.5M
- TVRD 22.5K
- Earning Date
- KOPN 08-12-2025
- TVRD 08-14-2025
- Dividend Yield
- KOPN N/A
- TVRD N/A
- EPS Growth
- KOPN N/A
- TVRD N/A
- EPS
- KOPN N/A
- TVRD N/A
- Revenue
- KOPN $46,959,478.00
- TVRD N/A
- Revenue This Year
- KOPN $8.02
- TVRD N/A
- Revenue Next Year
- KOPN $20.99
- TVRD N/A
- P/E Ratio
- KOPN N/A
- TVRD N/A
- Revenue Growth
- KOPN 13.03
- TVRD N/A
- 52 Week Low
- KOPN $0.56
- TVRD $8.13
- 52 Week High
- KOPN $2.50
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- KOPN 51.83
- TVRD 62.10
- Support Level
- KOPN $1.68
- TVRD $22.91
- Resistance Level
- KOPN $2.04
- TVRD $27.25
- Average True Range (ATR)
- KOPN 0.17
- TVRD 1.63
- MACD
- KOPN -0.02
- TVRD 0.36
- Stochastic Oscillator
- KOPN 38.18
- TVRD 86.79
About KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.